Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.46 |
| ▸ | CPT1A | P50416 | 2/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 4/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | USP9X | Q93008 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002060 | 0.86 | CPT1A (0.44) | AKR1C3CPT1AALDH1A1RORCMGAM | |
| SCHEMBL2003877 | 0.85 | CPT1A (0.45) | AKR1C3CPT1AALDH1A1RORCMGAM | |
| SCHEMBL2000724 | 0.85 | CPT1A (0.44) | CPT1AALDH1A1RORC | |
| SCHEMBL2008008 | 0.85 | CPT1A (0.44) | CPT1AALDH1A1RORCMGAMMEN1 | |
| SCHEMBL2005427 | 0.85 | CPT1A (0.49) | AKR1C3CPT1AALDH1A1RORCMEN1 | |
| SCHEMBL2000863 | 0.83 | CPT1A (0.43) | CPT1A | |
| SCHEMBL2007284 | 0.83 | CPT1A (0.52) | AKR1C3CPT1AAKR1C1RORCMEN1 | |
| SCHEMBL2005390 | 0.82 | CPT1A (0.42) | CPT1AALDH1A1RORCMGAM | |
| SCHEMBL1997441 | 0.81 | CPT1A (0.43) | CPT1AALDH1A1MEN1KMT2A | |
| SCHEMBL4238185 | 0.81 | CPT1A (0.42) | CPT1ARORCMGAMNR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | AKR1C3 431/4885CPT1A 3067/4885AKR1C1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.